At first glance, the findings appear encouraging: CREST and POTOMAC demonstrated modest but statistically significant improvements in event-free survival (EFS) and disease-free survival (DFS), ...
Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results